Improved Transdermal Delivery of Rabies Vaccine using Iontophoresis Coupled Microneedle Approach
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
AIM: This study was aimed to develop rabies vaccine incorporated microneedle (MN) patches and evaluate the immunogenicity of prepared formulations in combination with iontophoresis.
METHODS: Patches comprising of polyvinyl pyrrolidone, hyaluronic acid and polyethylene glycol 400 were engineered by vacuum micromolding technique. Physical evaluation of patches included determination of folding endurance, % swelling and morphological features. In vitro release study was performed in skin simulant agarose gel using model drug (methylene blue) loaded patches. In vitro insertion ability was assessed using stratum corneum simulant parafilm. In vivo insertion study was performed in rats. Immunogenicity was evaluated in dogs by determining immunoglobulin G (IgG) and rabies virus neutralizing antibodies (RVNA) titer.
RESULTS: Patches displayed uniformly distributed microprojections with pointed tips and smooth surface, ~ 70% swelling, remained intact for ~ 200 foldings and successfully penetrated the parafilm. The area covered by model drug across agarose gel was almost double following treatment with MN-iontophoresis combination (MNdi) compared to MN alone (MNdo). Histological examination of rat skin treated with vaccine laden MN (MNvo) and MN-iontophoresis combination (MNvi) confirmed the formation of grooves in epidermis without any damage to the deep vasculature. A ~ 73% and ~ 206% increase (compared to untreated counterpart) was observed in the IgG titer of MNvo and MNvi treated dogs, respectively. The RVNA titer was increased by ~ 1.2 and ~ 2.2 times (compared to threshold value) after MNvo and MNvi treatment, respectively.
CONCLUSION: MN-iontophoresis combination provided relatively potent immunogenic response over the conventional intramuscular injection, hence, can be used for administering vaccines transcutaneously.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:40 |
|---|---|
| Enthalten in: |
Pharmaceutical research - 40(2023), 8 vom: 05. Aug., Seite 2039-2049 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Arshad, Muhammad Sohail [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8002-74-2 |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 24.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11095-023-03521-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356887553 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356887553 | ||
| 003 | DE-627 | ||
| 005 | 20231226071420.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11095-023-03521-0 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1189.xml |
| 035 | |a (DE-627)NLM356887553 | ||
| 035 | |a (NLM)37186072 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Arshad, Muhammad Sohail |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improved Transdermal Delivery of Rabies Vaccine using Iontophoresis Coupled Microneedle Approach |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 24.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a AIM: This study was aimed to develop rabies vaccine incorporated microneedle (MN) patches and evaluate the immunogenicity of prepared formulations in combination with iontophoresis | ||
| 520 | |a METHODS: Patches comprising of polyvinyl pyrrolidone, hyaluronic acid and polyethylene glycol 400 were engineered by vacuum micromolding technique. Physical evaluation of patches included determination of folding endurance, % swelling and morphological features. In vitro release study was performed in skin simulant agarose gel using model drug (methylene blue) loaded patches. In vitro insertion ability was assessed using stratum corneum simulant parafilm. In vivo insertion study was performed in rats. Immunogenicity was evaluated in dogs by determining immunoglobulin G (IgG) and rabies virus neutralizing antibodies (RVNA) titer | ||
| 520 | |a RESULTS: Patches displayed uniformly distributed microprojections with pointed tips and smooth surface, ~ 70% swelling, remained intact for ~ 200 foldings and successfully penetrated the parafilm. The area covered by model drug across agarose gel was almost double following treatment with MN-iontophoresis combination (MNdi) compared to MN alone (MNdo). Histological examination of rat skin treated with vaccine laden MN (MNvo) and MN-iontophoresis combination (MNvi) confirmed the formation of grooves in epidermis without any damage to the deep vasculature. A ~ 73% and ~ 206% increase (compared to untreated counterpart) was observed in the IgG titer of MNvo and MNvi treated dogs, respectively. The RVNA titer was increased by ~ 1.2 and ~ 2.2 times (compared to threshold value) after MNvo and MNvi treatment, respectively | ||
| 520 | |a CONCLUSION: MN-iontophoresis combination provided relatively potent immunogenic response over the conventional intramuscular injection, hence, can be used for administering vaccines transcutaneously | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a hyaluronic acid | |
| 650 | 4 | |a iontophoresis | |
| 650 | 4 | |a microneedles | |
| 650 | 4 | |a polyvinyl pyrrolidone | |
| 650 | 4 | |a rabies vaccine | |
| 650 | 7 | |a Rabies Vaccines |2 NLM | |
| 650 | 7 | |a Paraffin |2 NLM | |
| 650 | 7 | |a 8002-74-2 |2 NLM | |
| 650 | 7 | |a Sepharose |2 NLM | |
| 650 | 7 | |a 9012-36-6 |2 NLM | |
| 650 | 7 | |a Immunoglobulin G |2 NLM | |
| 700 | 1 | |a Hussain, Saad |e verfasserin |4 aut | |
| 700 | 1 | |a Zafar, Saman |e verfasserin |4 aut | |
| 700 | 1 | |a Rana, Sadia Jafar |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Nadia |e verfasserin |4 aut | |
| 700 | 1 | |a Jalil, Najmusama Abdul |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmad, Zeeshan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Pharmaceutical research |d 1984 |g 40(2023), 8 vom: 05. Aug., Seite 2039-2049 |w (DE-627)NLM012597236 |x 1573-904X |7 nnns |
| 773 | 1 | 8 | |g volume:40 |g year:2023 |g number:8 |g day:05 |g month:08 |g pages:2039-2049 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11095-023-03521-0 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 40 |j 2023 |e 8 |b 05 |c 08 |h 2039-2049 | ||